Chris Emery

Chris Emery has extensive experience in the healthcare industry, particularly in the field of molecular diagnostics and liquid biopsy. Chris has held various leadership positions in companies such as PreludeDx, where they served as the Vice President of Strategic Marketing and Business Development. Chris has also been an Advisory Board Member for nRichDX, a company focused on enabling the liquid biopsy transformation.

Chris Emery was the Chief Business Officer and VP of Business Development at HALO Precision Diagnostics, where they played a key role in integrating molecular diagnostics with the company's existing imaging/radiology business. Chris was also the President and CEO of Curetis USA, responsible for introducing the company's testing platforms for infectious diseases to the US market.

Prior to these roles, Chris Emery held positions at Menarini Silicon Biosystems, Abbott, Novartis, Combimatrix, Agendia, and Response Genetics, where they gained experience in marketing, sales, and business development for molecular diagnostic tests, with a focus on oncology. Throughout their career, they have been dedicated to improving patient outcomes and advancing precision medicine in the fight against cancer.

Chris Emery has an Executive MBA from Pepperdine Graziadio Business School, with a focus on Business Administration and Management. They also hold a Bachelor of Arts degree in Communication and Media Studies from UC San Diego, as well as a minor in Public Health from the same institution.